Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Epigenetically regulated PCDHB15 impairs aggressiveness of metastatic melanoma cells.
Carrier A, Desjobert C, Lobjois V, Rigal L, Busato F, Tost J, Ensenyat-Mendez M, Marzese DM, Pradines A, Favre G, Lamant L, Lanfrancone L, Etievant C, Arimondo PB, Riond J. Carrier A, et al. Among authors: etievant c. Clin Epigenetics. 2022 Nov 28;14(1):156. doi: 10.1186/s13148-022-01364-x. Clin Epigenetics. 2022. PMID: 36443814 Free PMC article.
Demethylation by low-dose 5-aza-2'-deoxycytidine impairs 3D melanoma invasion partially through miR-199a-3p expression revealing the role of this miR in melanoma.
Desjobert C, Carrier A, Delmas A, Marzese DM, Daunay A, Busato F, Pillon A, Tost J, Riond J, Favre G, Etievant C, Arimondo PB. Desjobert C, et al. Among authors: etievant c. Clin Epigenetics. 2019 Jan 16;11(1):9. doi: 10.1186/s13148-018-0600-2. Clin Epigenetics. 2019. PMID: 30651148 Free PMC article.
DNA methylome combined with chromosome cluster-oriented analysis provides an early signature for cutaneous melanoma aggressiveness.
Carrier A, Desjobert C, Ponger L, Lamant L, Bustos M, Torres-Ferreira J, Henrique R, Jeronimo C, Lanfrancone L, Delmas A, Favre G, Daunay A, Busato F, Hoon DSB, Tost J, Etievant C, Riond J, Arimondo PB. Carrier A, et al. Among authors: etievant c. Elife. 2022 Sep 20;11:e78587. doi: 10.7554/eLife.78587. Elife. 2022. PMID: 36125262 Free PMC article.
F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103.
Etiévant C, Kruczynski A, Barret JM, Perrin D, van Hille B, Guminski Y, Hill BT. Etiévant C, et al. Cancer Chemother Pharmacol. 2000;46(2):101-13. doi: 10.1007/s002800000133. Cancer Chemother Pharmacol. 2000. PMID: 10972479
36 results